Important Note This article is for educational purposes only. It does not constitute medical advice.
Semaglutide is a medicine that belongs to a class known as GLP-1 receptor agonists. It was originally developed for the treatment of type 2 diabetes and later approved for weight management. To understand why it can affect both blood sugar and body weight, it is helpful to look at how it interacts with the body’s natural systems.
What is GLP-1?
GLP-1 stands for Glucagon-Like Peptide-1. It is a hormone naturally produced in the intestines after eating. GLP-1 plays several important roles in the body:
- It signals the brain to reduce appetite.
- It slows down the emptying of the stomach, which helps people feel full for longer.
- It stimulates the pancreas to release insulin when blood sugar levels are high.
- It reduces the release of glucagon (a hormone that raises blood sugar).
These combined effects help regulate blood sugar levels and food intake after meals.
How Semaglutide Mimics GLP-1
Semaglutide is a synthetic version of GLP-1 that has been modified to last much longer in the body. While natural GLP-1 breaks down very quickly (within minutes), semaglutide remains active for about a week. This allows it to be given as a once-weekly injection.
When semaglutide is injected, it binds to and activates GLP-1 receptors throughout the body. By doing this, it produces similar effects to natural GLP-1, but in a stronger and more sustained way.
Main Effects of Semaglutide in the Body
Semaglutide influences several processes that are relevant to both diabetes and weight management:
| Effect | How It Happens | Result |
|---|---|---|
| Reduced appetite | Acts on areas of the brain that control hunger | Lower calorie intake |
| Slower gastric emptying | Delays food leaving the stomach | Longer feeling of fullness |
| Increased insulin secretion | Stimulates the pancreas when blood sugar is high | Better blood sugar control |
| Reduced glucagon secretion | Lowers the release of glucagon from the pancreas | Prevents blood sugar from rising too much |
| Effects on reward pathways | May reduce cravings for certain foods | Helps with overall eating behaviour |
These effects work together. By reducing hunger and slowing digestion, semaglutide helps people eat less. At the same time, its effects on insulin and glucagon help improve blood sugar control in people with type 2 diabetes.
Why Semaglutide Affects Weight
Weight loss with semaglutide is mainly driven by reduced calorie intake rather than by increasing the number of calories the body burns. Because it affects brain pathways involved in appetite and food reward, many people report feeling less hungry and having fewer cravings while taking it.
Clinical trials have shown that this reduction in appetite and food intake leads to meaningful weight loss over time when semaglutide is combined with diet and exercise.
How Long Does Semaglutide Stay in the Body?
One of the key features of semaglutide is its long duration of action. After injection, it stays in the bloodstream for approximately one week. This is why it only needs to be taken once per week. The long-lasting effect is achieved through chemical modifications that prevent it from being broken down quickly by the body.
Comparison with Natural GLP-1
| Feature | Natural GLP-1 | Semaglutide |
|---|---|---|
| Duration in body | A few minutes | About 1 week |
| Administration | Not practical for treatment | Once-weekly injection |
| Effect on appetite | Present but short-lived | Strong and sustained |
| Effect on blood sugar | Present | Strong and sustained |
Because semaglutide lasts much longer than natural GLP-1, its effects on appetite and blood sugar are much more consistent throughout the week.
Summary
Semaglutide works by mimicking the natural hormone GLP-1. It activates GLP-1 receptors in the brain, gut, and pancreas. This leads to reduced appetite, slower digestion, increased insulin release, and lower glucagon levels. These combined actions help lower blood sugar in people with type 2 diabetes and support weight loss by reducing calorie intake. The long duration of semaglutide in the body allows it to be given just once per week, providing steady effects throughout the dosing interval.
References
- ClinicalTrials.gov – STEP and SUSTAIN Programmes (Semaglutide).
- Marso, S.P. et al. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine.
- Wilding, J.P.H. et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine.
- Medicines and Healthcare products Regulatory Agency (MHRA) – Guidance on GLP-1 receptor agonists.
For more information, see our main guide on Semaglutide and our comparison article Retatrutide vs Semaglutide vs Tirzepatide.
Last Updated: July 2026